KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+86-022-82164980
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
| Catalog Number | KMP2304 |
|---|---|
| Product Name | Human CD274 Protein, Fc Tag, Avi Tag |
| Product Description | The Human CD274 Protein(KMP2304) is produced in HEK293 Cells and the target gene encoding Phe19-Thr239 is expressed with a Fc, Avi tag at the C-terminus. |
| Molecular Weight | 25.3 kDa |
| Alias | programmed cell death 1 ligand 1, CD274 |
| Species | Human |
| Host | HEK293 Cells |
| Size | 50ug, 100ug, 200ug |
| Purification | Affinity purification |
| Purity | >95% as determined by SDS-PAGE |
| Endotoxin | <1.0 EU/ug determined by the LAL method |
| Buffer | 20mM PB, 150mM NaCl, pH7.4 |
| Uniprot | Q9NZQ7 |
| SDS-PAGE |  |
| Function | 1.Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) . 2.The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival . The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Background | CD274, also known as B7-H1 or programmed death ligand 1(PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1(PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
| Storage | Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles. |
| Note | This product is for research use only. |
| References | 1.Nat. Med. 5:1365-1369 (1999) 2.J. Exp. Med. 192:1027-1034 (2000) 3.Nature 549:106-110 (2017) 4.Nature 549:101-105 (2017) 5.Nature 549:106-110 (2017) 6.Nature 549:101-105 (2017) |
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：[email protected]
Hot Line： +86-022-82164980
Technical Support：[email protected]
